EPAS1 and kidney cancer: He has used genetic models to address the contribution of HIF-2α, compared to HIF-1α, in hypoxia regulation in the skin and the liver (47) and subsequently presented the effects of an HIF-2α antagonist, PT2399, in preclinical kidney cancer models (48).